ROCHE's VERSED (MIDAZOLAM) REVISED LABELING

ROCHE's VERSED (MIDAZOLAM) REVISED LABELING that calls for lower dosage in elderly or debilitated patients adequately addresses adverse reaction concerns, FDA's Anesthetic & Life Support Drugs advisory committee agreed at its meeting May 19. The committee had recommended a lower surgical dose for at-risk patients at its last meeting in December. Roche Associate Director for Drug Regulatory Affairs Karen Church reported that since December the Versed package insert has been revised to state that the initial dose for chronically ill or debilitated patients is "approximately 1 to 1.5 mg," a 50% reduction from the previous indication. The labeling also states that: "the total dose should be lowered by a total of 55-60% in elderly or debilitated patients receiving a narcotic or CNS depressant premedication." Labeling previously stated that dosage "should be lowered by about 25% to 30% if narcotic medication is used" and that patients 60 years or older may require lower doses "by about 30%" than younger patients. In additional revisions, a statement has been added in boldface that "when used for conscious sedation, Versed should not be administered by rapid or single bolus I.V. administration." For average healthy adults, the total recommended dose is now 0.1 mg/kg; it was previously 0.1 to 0.15 mg/kg. The recommendation that "in rare cases, a total dose of up to 0.2 mg/kg may be necessary" has been deleted from the labeling. The labeling also adds that in titrating dose to individual needs a dose lower, i.e. lower than 0.1 mg/kg total dose, may suffice. Church noted that FDA has also approved a 1 mg/ml formulation that Roche will launch following receipt of a final approval letter. Versed is currently available in package configurations equivalent to 5 mg/ml. In addition, Church said Roche disseminated a "Dear Doctor" letter the first week in February that "reemphasized the need for individualization of dose; the proper methods for administering the drug intravenously, the need for early recognition and treatment of under ventilation and apnea; and reinforced the possibility of respiratory and cardiac events." Roche's James Braico reported that from April 1986 until March 1987 there have been 48 cases reported of apnea, cardiopulmonary events and/or death (23 cases). Church concluded that based on Roche's analysis of available data the company "does not believe that dosage per se, ASA status, or age, per se, is an adequate predictor of cardiovascular or respiratory adverse events." However, Church stated that a reduction of dosage in elderly and in patients who have a narcotic or CNS premedication "is essential."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

No Surprise Here: Foreign Drug Facilities Should Expect Surprise Inspections, US FDA Says

 
• By 

The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.

Base Benefit-Risk Decisions On Data, Not Opinion And Passion, CDER’s Tidmarsh Says

 
• By 

New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.

Pink Sheet Podcast: FDA’s New Top Drug Regulator, Sarepta’s Options After Elevidys Stand-Off

Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.